Company search
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Portfolio yield
Data as at : 31/03/2026
| % |
|---|
| 0.1 |
Please note that the above fields are displayed for companies that have reported this data to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 28/02/2026
| Investment | % of total assets |
|---|---|
| Soleno Therapeutics Inc | 5.5 |
| Alnylam Pharmaceuticals Inc | 4.5 |
| Insmed Inc | 3.9 |
| Ascendis Pharma AS ADR | 3.4 |
| Sv Bcof | 3.4 |
| NovoCure Ltd | 3.3 |
| Autolus Therapeutics PLC ADR | 3.1 |
| Madrigal Pharmaceuticals Inc | 3.1 |
| Crinetics Pharmaceuticals Inc | 2.9 |
| Scotiabank Sofr + 1.10% 11/25 Usd3 Schroders Receive | -9.4 |
Geographic breakdown
Data as at : 28/02/2026
| Country | % of total assets |
|---|---|
| USA | 68.8 |
| UK | 8.6 |
| Cayman Islands | 5.8 |
| Netherlands | 5.1 |
| Denmark | 3.8 |
| Guernsey | 3.0 |
| Singapore | 1.9 |
| France | 1.8 |
| Canada | 0.9 |
| Switzerland | 0.4 |
| Australia | 0.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 28/02/2026
| Industry | % of total assets |
|---|---|
| Healthcare | 100.6 |
| Cash Equivalents | 0.9 |
| Preferred | 0.3 |
| Government Related | -9.4 |
Scroll
Asset breakdown
Data as at : 28/02/2026
| Asset | % of total assets |
|---|---|
| Stock | 108.4 |
| Bond | -9.4 |
| Cash/Cash equivalents | 0.9 |
Detailed asset breakdown
Data as at : 28/02/2026
| Asset | % of total assets |
|---|---|
| North America - stock | 83.1 |
| Other - stock | 13.8 |
| Asia (excl Japan) - stock | 4.1 |
| Europe - Mid-cap stock | 2.6 |
| Europe - Large-cap stock | 1.4 |
| UK - Small core/value stock | 1.3 |
| Europe - Small-cap stock | 1.3 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
